1
|
Bashyal S, Seo JE, Choi YW, Lee S. Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach. J Control Release 2021; 338:644-661. [PMID: 34481926 DOI: 10.1016/j.jconrel.2021.08.060] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 07/26/2021] [Accepted: 08/31/2021] [Indexed: 12/19/2022]
Abstract
Despite many ongoing and innovative approaches, there are still formidable challenges in the clinical translation of oral peptide drugs into marketable products due to their low absorption and poor bioavailability. Herein, a novel nanocarrier platform was developed that employs a hydrophobic ion-pairing (HIP) of model peptide (insulin) and the anionic bile salt (sodium glycodeoxycholate, SGDC), and markedly improves intestinal absorption via the bile acid pathway. The developed HIP-nanocomplexes (C1 and C2) were optimized, characterized, and in vitro and in vivo evaluation were performed to assess oral efficacy of these system. The optimal molar ratios of C1 and C2-nanocomplexes were 30:1 and 6:1 (SGDC:insulin), respectively. Compared to the insulin solution, the C1 and C2 nanocomplexes significantly enhanced the permeation of insulin across the Caco-2 cell monolayers, with 6.36- and 4.05-fold increases in apparent permeability, respectively. Uptake mechanism studies were conducted using different endocytosis inhibitors and apical sodium-dependent bile acid transporter (ASBT)-transfected MDCK cells, which demonstrated the involvement of the energy-dependent ASBT-mediated active transport. Furthermore, the intrajejunal administration of C1 and C2 resulted in their pharmacological availabilities (PA) being 6.44% and 0.10%, respectively, indicating increased potential for C1, when compared to C2. Similarly, the PA and the relative bioavailability with intrajejunal administration of the C1 were 17.89-fold and 16.82-fold greater than those with intracolonic administration, respectively, confirming better jejunal absorption of C1. Overall, these findings indicate that the HIP-nanocomplexes could be a prominent platform for the effective delivery of peptides with improved intestinal absorption.
Collapse
Affiliation(s)
- Santosh Bashyal
- College of Pharmacy, Keimyung University, Daegu, Republic of Korea; Center for Forensic Pharmaceutical Science, Keimyung University, Daegu, Republic of Korea
| | - Jo-Eun Seo
- College of Pharmacy, Keimyung University, Daegu, Republic of Korea
| | - Young Wook Choi
- College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea
| | - Sangkil Lee
- College of Pharmacy, Keimyung University, Daegu, Republic of Korea; Center for Forensic Pharmaceutical Science, Keimyung University, Daegu, Republic of Korea.
| |
Collapse
|
2
|
Lavanya MN, Preethi R, Moses JA, Anandharamakrishnan C. Aerosol-based Pulmonary Delivery of Therapeutic Molecules from Food Sources: Delivery Mechanism, Research Trends, and the Way Forward. FOOD REVIEWS INTERNATIONAL 2021. [DOI: 10.1080/87559129.2021.1888971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- M. N. Lavanya
- Computational Modeling and Nanoscale Processing Unit, Indian Institute of Food Processing Technology (IIFPT), Ministry of Food Processing Industries, Govt. Of India, India
| | - R. Preethi
- Computational Modeling and Nanoscale Processing Unit, Indian Institute of Food Processing Technology (IIFPT), Ministry of Food Processing Industries, Govt. Of India, India
| | - J. A. Moses
- Computational Modeling and Nanoscale Processing Unit, Indian Institute of Food Processing Technology (IIFPT), Ministry of Food Processing Industries, Govt. Of India, India
| | - C. Anandharamakrishnan
- Computational Modeling and Nanoscale Processing Unit, Indian Institute of Food Processing Technology (IIFPT), Ministry of Food Processing Industries, Govt. Of India, India
| |
Collapse
|
3
|
Oral peptide delivery: challenges and the way ahead. Drug Discov Today 2021; 26:931-950. [PMID: 33444788 DOI: 10.1016/j.drudis.2021.01.001] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2020] [Revised: 10/16/2020] [Accepted: 01/06/2021] [Indexed: 12/14/2022]
Abstract
Peptides and proteins have emerged as potential therapeutic agents and, in the search for the best treatment regimen, the oral route has been extensively evaluated because of its non-invasive and safe nature. The physicochemical properties of peptides and proteins along with the hurdles in the gastrointestinal tract (GIT), such as degrading enzymes and permeation barriers, are challenges to their delivery. To address these challenges, several conventional and novel approaches, such as nanocarriers, site-specific and stimuli specific delivery, are being used. In this review, we discuss the challenges to the oral delivery of peptides and the approaches used to tackle these challenges.
Collapse
|
4
|
Presas E, Tovar S, Cuñarro J, O'Shea JP, O'Driscoll CM. Pre-Clinical Evaluation of a Modified Cyclodextrin-Based Nanoparticle for Intestinal Delivery of Liraglutide. J Pharm Sci 2020; 110:292-300. [PMID: 33152374 DOI: 10.1016/j.xphs.2020.10.058] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 10/29/2020] [Accepted: 10/29/2020] [Indexed: 01/27/2023]
Abstract
New therapeutic approaches have been developed during recent years for the management of diabetic patients, with glucagon-like peptides analogues (GLP-1 analogues) emerging as one of the most useful therapies. However, as with human insulin analogues, translation of GLP-1 analogues into oral pharmaceutical products has been limited due to reduced oral bioavailability. Nanoparticle (NP) formulations have been investigated due to their potential to protect the drug cargo and enhance bioavailability. This study describes the pre-clinical development of a cyclodextrin-based NP formulation containing the GLP-1 analogue liraglutide for intestinal administration. A cationic amphiphilic cyclodextrin (click propyl-amine cyclodextrin (CD)) was selected as the primary complexing agent for the peptide. The resulting NPs presented an average size of 101 ± 8 nm, low polydispersity index (0.240), a negative zeta potential (-35 ± 7 mV), complete association efficiency and peptide loading of 5.0%. The optimized prototype exhibited colloidal stability in intestinal-biorelevant media up to 4 h, protecting the entrapped liraglutide from degradation by proteolytic enzymes. Intestinal administration in rats revealed effective protection and delivery of liraglutide, with a similar pharmacological response in blood glucose levels relative to subcutaneous administration of free solution. These results demonstrate the potential of the CD based formulation for further development.
Collapse
Affiliation(s)
- Elena Presas
- Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland
| | - Sulay Tovar
- Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS), Group of Diabesity, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Juan Cuñarro
- Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS), Group of Diabesity, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Joseph P O'Shea
- Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland
| | | |
Collapse
|
5
|
Sharma J, Larkin J. Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer. Front Pharmacol 2019; 10:324. [PMID: 31105556 PMCID: PMC6499178 DOI: 10.3389/fphar.2019.00324] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 03/18/2019] [Indexed: 12/14/2022] Open
Abstract
The suppressor of cytokine signaling (SOCS) family of intracellular proteins has a vital role in the regulation of the immune system and resolution of inflammatory cascades. SOCS1, also called STAT-induced STAT inhibitor (SSI) or JAK-binding protein (JAB), is a member of the SOCS family with actions ranging from immune modulation to cell cycle regulation. Knockout of SOCS1 leads to perinatal lethality in mice and increased vulnerability to cancer, while several SNPs associated with the SOCS1 gene have been implicated in human inflammation-mediated diseases. In this review, we describe the mechanism of action of SOCS1 and its potential therapeutic role in the prevention and treatment of autoimmunity and cancer. We also provide a brief outline of the other JAK inhibitors, both FDA-approved and under investigation.
Collapse
Affiliation(s)
- Jatin Sharma
- Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL, United States
| | - Joseph Larkin
- Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL, United States
| |
Collapse
|
6
|
Poovi G, Damodharan N. Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2018. [DOI: 10.1016/j.fjps.2018.04.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
7
|
Howick K, Alam R, Chruscicka B, Kandil D, Fitzpatrick D, Ryan AM, Cryan JF, Schellekens H, Griffin BT. Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization. Int J Pharm 2017; 536:63-72. [PMID: 29175643 DOI: 10.1016/j.ijpharm.2017.11.051] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 10/29/2017] [Accepted: 11/22/2017] [Indexed: 02/01/2023]
Abstract
There is an impetus to provide appropriate sustained release oral delivery vehicles to protect biofunctional peptide loads from gastric degradation in vivo. This study describes the generation of a high load capacity pellet formulation for sustained release of a freely water-soluble dairy-derived hydrolysate, FHI-2571. The activity of this novel peptidic ghrelin receptor agonist is reported using in vitro calcium mobilization assays. Conventional extrusion spheronization was then used to prepare peptide-loaded pellets which were subsequently coated with ethylcellulose (EC) film coats using a fluid bed coating system in bottom spray (Wurster) mode. Aqueous-based EC coating dispersions produced mechanically brittle coats which fractured due to osmotic pressure build-up within pellets in simulated media. In contrast, an ethanolic-based EC coating solution provided robust, near zero-order release in both USP Type 1 and Type 4 dissolution studies. Interestingly, the functionality of aqueous-based EC film coats was restored by first layering pellets with a methacrylic acid copolymer (MA) subcoat, thereby hindering pellet core swelling in acidic media. Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS) was utilised as a complementary technique to confirm the results seen in USP dissolution studies. Retention of activity of the ghrelinergic peptide hydrolysate in the final encapsulated product was confirmed as being greater than 80%. The described pellet formulation is amenable to oral dosing in small animal studies in order to assess in vivo efficacy of the whey-derived ghrelinergic hydrolysate. In more general terms, it is also suitable as a delivery vehicle for peptide-based bioactives to special population groups e.g paediatric and geriatric.
Collapse
Affiliation(s)
- Ken Howick
- School of Pharmacy, University College Cork, Cork, Ireland; Department of Anatomy & Neuroscience, University College Cork, Cork, Ireland; Food for Health Ireland, University College Cork, Cork, Ireland
| | - Ryan Alam
- School of Pharmacy, University College Cork, Cork, Ireland
| | - Barbara Chruscicka
- Department of Anatomy & Neuroscience, University College Cork, Cork, Ireland; APC Microbiome Institute, University College Cork, Cork, Ireland
| | - Dalia Kandil
- Department of Anatomy & Neuroscience, University College Cork, Cork, Ireland; Food for Health Ireland, University College Cork, Cork, Ireland
| | - Dara Fitzpatrick
- Department of Chemistry, Analytical and Biological Chemistry Research Facility (ABCRF), University College Cork, Cork, Ireland
| | - Aoife M Ryan
- Food for Health Ireland, University College Cork, Cork, Ireland; Department of Food & Nutritional Sciences, University College Cork, Cork, Ireland
| | - John F Cryan
- Department of Anatomy & Neuroscience, University College Cork, Cork, Ireland; APC Microbiome Institute, University College Cork, Cork, Ireland
| | - Harriët Schellekens
- Department of Anatomy & Neuroscience, University College Cork, Cork, Ireland; Food for Health Ireland, University College Cork, Cork, Ireland; APC Microbiome Institute, University College Cork, Cork, Ireland
| | - Brendan T Griffin
- School of Pharmacy, University College Cork, Cork, Ireland; Food for Health Ireland, University College Cork, Cork, Ireland.
| |
Collapse
|
8
|
Zupančič O, Rohrer J, Thanh Lam H, Grießinger JA, Bernkop-Schnürch A. Development and in vitro characterization of self-emulsifying drug delivery system (SEDDS) for oral opioid peptide delivery. Drug Dev Ind Pharm 2017; 43:1694-1702. [DOI: 10.1080/03639045.2017.1338722] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Ožbej Zupančič
- Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innsbruck, Austria
| | - Julia Rohrer
- Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innsbruck, Austria
| | - Hung Thanh Lam
- Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innsbruck, Austria
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam
| | - Julia Anita Grießinger
- Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innsbruck, Austria
| | - Andreas Bernkop-Schnürch
- Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Innsbruck, Austria
| |
Collapse
|
9
|
Zupančič O, Bernkop-Schnürch A. Lipophilic peptide character – What oral barriers fear the most. J Control Release 2017; 255:242-257. [DOI: 10.1016/j.jconrel.2017.04.038] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 04/21/2017] [Accepted: 04/25/2017] [Indexed: 10/19/2022]
|
10
|
Varamini P, Mansfeld FM, Giddam AK, Steyn F, Toth I. New gonadotropin-releasing hormone glycolipids with direct antiproliferative activity and gonadotropin-releasing potency. Int J Pharm 2017; 521:327-336. [PMID: 28232269 DOI: 10.1016/j.ijpharm.2017.02.054] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 02/10/2017] [Accepted: 02/19/2017] [Indexed: 11/19/2022]
Affiliation(s)
- Pegah Varamini
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
| | - Friederike M Mansfeld
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
| | - Ashwini Kumar Giddam
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
| | - Frederik Steyn
- The University of Queensland Centre for Clinical Research and the School of Biomedical Sciences, Brisbane, Australia
| | - Istvan Toth
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia; School of Pharmacy, The University of Queensland, Brisbane, Australia; Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
| |
Collapse
|
11
|
Niu Z, Tedesco E, Benetti F, Mabondzo A, Montagner IM, Marigo I, Gonzalez-Touceda D, Tovar S, Diéguez C, Santander-Ortega MJ, Alonso MJ. Rational design of polyarginine nanocapsules intended to help peptides overcoming intestinal barriers. J Control Release 2017; 263:4-17. [PMID: 28235590 DOI: 10.1016/j.jconrel.2017.02.024] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 02/02/2017] [Accepted: 02/19/2017] [Indexed: 02/04/2023]
Abstract
The aim of this work was to rationally design and characterize nanocapsules (NCs) composed of an oily core and a polyarginine (PARG) shell, intended for oral peptide delivery. The cationic polyaminoacid, PARG, and the oily core components were selected based on their penetration enhancing properties. Insulin was adopted as a model peptide to assess the performance of the NCs. After screening numerous formulation variables, including different oils and surfactants, we defined a composition consisting of oleic acid, sodium deoxycholate (SDC) and Span 80. This selected NCs composition, produced by the solvent displacement technique, exhibited the following key features: (i) an average size of 180nm and a low polydispersity (0.1), (ii) a high insulin association efficacy (80-90% AE), (iii) a good colloidal stability upon incubation in simulated intestinal fluids (SIF, FaSSIF-V2, FeSSIF-V2), and (iv) the capacity to control the release of the associated insulin for >4h. Furthermore, using the Caco-2 model cell line, PARG nanocapsules were able to interact with the enterocytes, and reversibly modify the TEER of the monolayer. Both cell adhesion and membrane permeabilization could account for the pronounced transport of the NCs-associated insulin (3.54%). This improved interaction was also visualized by confocal fluorescent microscopy following oral administration of PARG nanocapsulesto mice. Finally, in vivo efficacy studies performed in normoglycemic rats showed a significant decrease in their plasma glucose levels after treatment. In conclusion, here we disclose key formulation elements for making possible the oral administration of peptides.
Collapse
Affiliation(s)
- Zhigao Niu
- Department of Pharmacy and Pharmaceutical Technology, CIMUS Research Institute, IDIS research Institute, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Erik Tedesco
- ECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, I-45100 Rovigo, Italy
| | - Federico Benetti
- ECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, I-45100 Rovigo, Italy
| | - Aloïse Mabondzo
- Service de Pharmacologie et d'Immunoanalyse, IBITECS, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | | | - Ilaria Marigo
- Veneto Institute of Oncology, IOV-IRCCS, 35128 Padova, Italy
| | - David Gonzalez-Touceda
- Biomedical Research Group, Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Sulay Tovar
- Biomedical Research Group, Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Carlos Diéguez
- Biomedical Research Group, Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Manuel J Santander-Ortega
- Department of Pharmacy and Pharmaceutical Technology, CIMUS Research Institute, IDIS research Institute, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; Cellular Neurobiology and Molecular Chemistry of the Central Nervous System Group, Universidad de Castilla-La Mancha, Spain
| | - María J Alonso
- Department of Pharmacy and Pharmaceutical Technology, CIMUS Research Institute, IDIS research Institute, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
| |
Collapse
|
12
|
Aw MS, Paniwnyk L. Overcoming T. gondii infection and intracellular protein nanocapsules as biomaterials for ultrasonically controlled drug release. Biomater Sci 2017; 5:1944-1961. [DOI: 10.1039/c7bm00425g] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
One of the pivotal matters of concern in intracellular drug delivery is the preparation of biomaterials containing drugs that are compatible with the host target.
Collapse
Affiliation(s)
- M. S. Aw
- School of Life Sciences
- Biomolecular and Sports Science
- Faculty of Health and Life Sciences
- Coventry University
- Coventry
| | - L. Paniwnyk
- School of Life Sciences
- Biomolecular and Sports Science
- Faculty of Health and Life Sciences
- Coventry University
- Coventry
| |
Collapse
|
13
|
Lipid-based nanocarriers for oral peptide delivery. Adv Drug Deliv Rev 2016; 106:337-354. [PMID: 27080735 DOI: 10.1016/j.addr.2016.04.001] [Citation(s) in RCA: 166] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 03/30/2016] [Accepted: 04/03/2016] [Indexed: 12/23/2022]
Abstract
This article is aimed to overview the lipid-based nanostructures designed so far for the oral administration of peptides and proteins, and to analyze the influence of their composition and physicochemical (particle size, zeta potential) and pharmaceutical (drug loading and release) properties, on their interaction with the gastro-intestinal environment, and the subsequent PK/PD profile of the associated drugs. The ultimate goal has been to highlight and comparatively analyze the key factors that may be determinant of the success of these nanocarriers for oral peptide delivery. The article ends with some prospects on the challenges to be addressed for the intended commercial success of these delivery vehicles.
Collapse
|
14
|
Griffin BT, Guo J, Presas E, Donovan MD, Alonso MJ, O'Driscoll CM. Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. Adv Drug Deliv Rev 2016; 106:367-380. [PMID: 27320644 DOI: 10.1016/j.addr.2016.06.006] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Revised: 06/07/2016] [Accepted: 06/10/2016] [Indexed: 12/17/2022]
Abstract
The influence of nanoparticle (NP) formulations on the pharmacokinetic, pharmacodynamic and biodistribution profiles of peptide- and protein-like drugs following oral administration is critically reviewed. The possible mechanisms of absorption enhancement and the effects of the physicochemical properties of the NP are examined. The potential advantages and challenges of physiologically-based pharmacokinetic (PBPK) modelling to help predict efficacy in man are discussed. The importance of developing and expanding the regulatory framework to help translate the technology into the clinic and accelerate the availability of oral nanoparticulate formulations is emphasized. In conclusion, opportunities for future work to improve the state of the art of oral nanomedicines are identified.
Collapse
|
15
|
Wang K, Qi J, Weng T, Tian Z, Lu Y, Hu K, Yin Z, Wu W. Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. Int J Nanomedicine 2014; 9:4991-9. [PMID: 25378925 PMCID: PMC4218918 DOI: 10.2147/ijn.s72560] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
A variety of nanoscale delivery systems have been shown to enhance the oral absorption of poorly water-soluble and poorly permeable drugs. However, the performance of these systems has seldom been evaluated simultaneously. The aim of this study was to compare the bioavailability enhancement effect of lipid-based nanocarriers with poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) to highlight the importance of the lipid composition, with cyclosporine A (CyA) as a model drug. CyA-loaded PLGA NPs, nanostructured lipid carriers (NLCs), and self-microemulsifying drug-delivery systems (SMEDDS) were prepared. The particle size of PLGA NPs (182.2±12.8 nm) was larger than that of NLCs (89.7±9.0 nm) and SMEDDS (26.9±1.9 nm). All vehicles are charged negatively. The entrapment efficiency of PLGA NPs and NLCs was 87.6%±1.6% and 80.3%±0.6%, respectively. In vitro release tests indicated that the cumulative release of CyA was lower than 4% from all vehicles, including Sandimmun Neoral®, according to the dialysis method. Both NLCs and SMEDDS showed high relative oral bioavailability, 111.8% and 73.6%, respectively, after oral gavage administration to beagle dogs, which was not statistically different from commercial Sandimmun Neoral®. However, PLGA NPs failed to achieve efficient absorption, with relative bioavailability of about 22.7%. It is concluded that lipid-based nanoscale drug-delivery systems are superior to polymeric NPs in enhancing oral bioavailability of poorly water-soluble and poorly permeable drugs.
Collapse
Affiliation(s)
- Kai Wang
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of Ministry of Education, Shanghai, People's Republic of China ; West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, People's Republic of China ; Tropical Crops Genetic Resources Institute, Hainan Provincial Engineering Research Center for Blumea Balsamifera, Chinese Academy of Tropical Agricultural Sciences, Danzhou, Hainan, People's Republic of China
| | - Jianping Qi
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of Ministry of Education, Shanghai, People's Republic of China
| | - Tengfei Weng
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of Ministry of Education, Shanghai, People's Republic of China ; West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Zhiqiang Tian
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of Ministry of Education, Shanghai, People's Republic of China
| | - Yi Lu
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of Ministry of Education, Shanghai, People's Republic of China
| | - Kaili Hu
- Murad Research Center for Modernized Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Zongning Yin
- West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Wei Wu
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of Ministry of Education, Shanghai, People's Republic of China
| |
Collapse
|
16
|
Varamini P, Toth I. Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain. Front Pharmacol 2013; 4:155. [PMID: 24379782 PMCID: PMC3862115 DOI: 10.3389/fphar.2013.00155] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Accepted: 11/27/2013] [Indexed: 12/29/2022] Open
Abstract
Endomorphins are endogenous opioid peptides that cause potent antinociception in rodent models of acute and neuropathic pain with less undesirable side effects than opioid alkaloids. However, endomorphins are poorly suited to clinical applications because of low membrane permeability and a susceptibility to enzymatic degradation. Glycosylation and lipidation have proven to be two of the most robust approaches for the generation of new therapeutic endomorphin derivatives. Conjugation with lipoamino acids (LAA) confers an amphipathic character to the peptide, which improved interaction between the peptide and the lipid bilayer of the cell membranes, increasing permeability. Glycosylation can also improve peptide stability and blood brain barrier (BBB) transport. It is believed that an endocytotic mechanism (transcytosis) is responsible for the systemic delivery of water-soluble glycopeptides. This review discusses the application of glycosylation and lipidation strategies to improve the drug-like properties of endomorphins. Pharmacologically active endomorphin analogs with less adverse effects are also discussed.
Collapse
Affiliation(s)
- Pegah Varamini
- Medicinal Chemistry Department, School of Chemistry and Molecular Biosciences, The University of Queensland Brisbane, QLD, Australia
| | - Istvan Toth
- Medicinal Chemistry Department, School of Chemistry and Molecular Biosciences, The University of Queensland Brisbane, QLD, Australia ; Medicinal Chemistry Department, School of Pharmacy, The University of Queensland Brisbane, QLD, Australia
| |
Collapse
|
17
|
Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2013. [DOI: 10.1007/s40005-013-0087-y] [Citation(s) in RCA: 111] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
18
|
Abstract
The peptide therapeutic market is one of the fastest growth areas of the pharmaceutical industry. Although few orally administered peptides are marketed and many are in different phases of clinical development, there is no marketed oral peptide therapeutic used for CNS disorders. The major challenges involved in orally delivering peptides to the brain relate to their enzymatic instability and inability to permeate across physiological barriers. The paucity of therapies for the treatment of brain diseases and the presence of the blood-brain barrier excluding 98% of therapeutic molecules necessitates parenteral administration. Various approaches have been applied to enhance oral peptide bioavailability, but only nanoparticulate strategies were able to deliver orally therapeutic peptides to the brain. Although industry may be reluctant to invest in developing oral peptide nanomedicines, the increasingly unmet clinical need and economic burden associated with brain diseases will fuel the development of the first marketed oral-to-brain peptide therapy.
Collapse
|
19
|
Araújo F, Fonte P, Santos HA, Sarmento B. Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? J Diabetes Sci Technol 2012; 6:1486-97. [PMID: 23294796 PMCID: PMC3570891 DOI: 10.1177/193229681200600630] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases worldwide. Current treatments are often associated with off-target effects and do not significantly impact disease progression. New therapies are therefore urgently needed to overcome this social burden. Glucagon-like peptide-1 (GLP-1), an incretin hormone, has been used to control T2DM symptomatology. However, the administration of peptide or proteins drugs is still a huge challenge in the pharmaceutical field, requiring administration by parenteral routes. This article reviews the main hurdles in oral administration of GLP-1 and focuses on the strategies utilized to overcome them.
Collapse
Affiliation(s)
- Francisca Araújo
- Department of Pharmaceutical Sciences, Centro de Investigação em Ciências da Saúde, Health Sciences Research Center,Instituto Superior de Ciências da Saúde, CESPU, Gandra, Portugal
- Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal
| | - Pedro Fonte
- Department of Pharmaceutical Sciences, Centro de Investigação em Ciências da Saúde, Health Sciences Research Center,Instituto Superior de Ciências da Saúde, CESPU, Gandra, Portugal
- Department of Chemistry, Faculty of Pharmacy, REQUIMTE, University of Porto, Porto, Portugal
| | - Hélder A. Santos
- Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
| | - Bruno Sarmento
- Department of Pharmaceutical Sciences, Centro de Investigação em Ciências da Saúde, Health Sciences Research Center,Instituto Superior de Ciências da Saúde, CESPU, Gandra, Portugal
- Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Porto, Portugal
| |
Collapse
|